Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Acceptability of Intravaginal LABTHERA-001 in Healthy Women
NCT05587283Phase 1Unknown
- Sponsor
- AtoGen
- Start
- Nov 2022
- Primary completion
- Apr 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lactobacillus plantarum ATG-K2 in bacterial vaginosis (BV) (6 arms), sponsored by AtoGen. Primary endpoints: Number of Adverse Events (AEs) at 35 days, Changes in Clinical Laboratory Tests up to 35 days and 3 more. Status: unknown.
02
Drugs
Lactobacillus plantarum ATG-K2
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT05587283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05587283.